Pfizer (PFE) announced on Thursday that its cancer drug regimen, Talzenna plus Xtandi, met the primary endpoint in a Phase 3 trial for a new indication in prostate cancer. The Phase 3 TALAPRO-3 study ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 Talapro-3 trial met its primary ...

Add Yahoo as a preferred source to see more of our stories on Google. Women who used the baby powder for decades are taking action against Johnson & Johnson [Reuters] A group of Scottish women have ...

Women who used the baby powder for decades are taking action against Johnson & Johnson A group of Scottish women have launched legal action against Johnson & Johnson accusing the firm of selling them ...

Former UFC Flyweight Champion Demetrious Johnson has shut down rumors of a comeback fight, after Muhammad Mokaev had claimed he was in negotiations to fight the retired ONE Hall of Famer. Johnson ...

Vancouver City Coun. Sean Orr is suing Mayor Ken Sim for defamation after he accused Orr of distributing illegal drugs, comments the councillor says were made for political gain. (March 10, 2026) ...

>No increased risk for thrombosis or bleeding seen with concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs. (HealthDay News) — For patients with prostate cancer, concurrent use of ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants, investigators found no evidence of an increase in patients' ...

March 5 (Reuters) - The U.S. Food and Drug Administration on ‌Thursday approved Johnson & Johnson's (JNJ.N), opens new tab treatment for a type of blood cancer, making it the third drug cleared under ...

Prostate cancer is the most common cancer in American men, with an estimated 333,830 new cases and 36,320 deaths projected for 2026 for the disease, according to the American Cancer Society. In the ...

German agrichemical giant Bayer said Wednesday it made a loss of 3.62 billion euros ($4.20 billion) in 2025 after it booked extra charges related to claims that its popular weedkiller causes blood ...